0 items

in your cart
$0.00

Prescription Drug Search

Strengths available for Azilect:

Azilect 0.5mg
Azilect 1mg

Search for a drug:

 

Browse Alphabetically:

A · B · C · D · E · F · G · H · I · J · K · L · M · N
O · P · Q · R · S · T · U · V · W · X · Y · Z · #

Information about ExpressMedsCanada.com

SSL Secured Website Certified Global Pharmacy Network Hacker Proof: Safe Shopping Experience 5th Anniversary 2002-2007

List of countries where we can ship Azilect:

  • Anguilla
  • Armenia
  • Bahamas
  • Belgium
  • Bermuda
  • Bosnia and Herzegovina
  • Bulgaria
  • Cayman Islands
  • Chile
  • Costa Rica
  • Denmark
  • Dominican Republic
  • Estonia
  • Guadeloupe
  • Guatemala
  • Iceland
  • India
  • Indonesia
  • Korea, Republic of
  • Mauritius
  • Morocco
  • New Zealand
  • Nicaragua
  • Norway
  • Paraguay
  • Poland
  • Qatar
  • Romania
  • Russian Federation
  • Saint Lucia
  • Seychelles
  • Singapore
  • Slovenia
  • South Africa
  • Sri Lanka
  • Thailand
  • Tunisia
  • United Arab Emirates
  • United Kingdom, UK
  • United States, US
View All Countries

Latest news releases on Azilect:

Teva cuts 2012 profit and sales forecasts - Businessweek

However it expects lower sales of its Parkinson's disease treatment Azilect and women's health products, and of Cephalon's sleep disorder drug Provigil. Shares of Teva Pharmaceutical Industries rose 68 cents to $39.26 in morning trading.

Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS - StreetInsider.com

COPAXONE of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million OTC net sales of ...

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 - StreetInsider.com

COPAXONE® of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million -- OTC net sales ...

Harel sees 24% upside for Teva - Globes - Israel Business Arena

Tepper expects strong sales growth from the consolidation of Cephalon and price hikes for its drugs, as well as for Teva's Copaxone and Azilect, increased prescriptions for Azilect and for inhaler's, and Teva's collaboration with Procter & Gamble (NYSE ...

Teva Pharmaceuticals' Disappointing Results - Seekingalpha.com

Global revenue for Copaxone rose 4% to $909 million from $838 million in the first quarter of 2011. Azilect revenue rose 9% to $72 million. Notwithstanding the positive growth trends for sales and net income, the company does face several obstacles.

Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI - Phramalive.com

Ladostigil was designed by Professor Marta Weinstock-Rosin of the Hebrew University of Jerusalem, inventor of Exelon® and Professor Moussa B.H. Youdim of the Technion Israel Institute of Technology, inventor of Azilect®. The drug substance was first ...

Customer Service
1-866-799-3435 - Use Discount Code 7500 | Contact Form
Copyright © 2012 ExpressMedsCanada.com All rights reserved. Disclaimer | Privacy Policy
Accepted Credit Cards and Payment: VISA, MASTERCARD and eCHECK